Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight to 2025…

first_img WhatsApp Facebook WhatsApp Pinterest Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight to 2025 – Non-beneficial Approval of Drugs Is Driving Growth – ResearchAndMarkets.com Pinterest Local NewsBusiness DUBLIN–(BUSINESS WIRE)–Feb 24, 2021– The “Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight 2025” report has been added to ResearchAndMarkets.com’s offering. The strategy opted by the BCL-2 inhibitor market and variety of drugs under clinical development are considered to be important steps in changing the overall therapeutic approach for the cancer treatment. The global BCL-2 inhibitor market is categorized as a well-designed, carefully controlled therapeutic market that targets the BCL-2 protein for killing the cancer cells. Companies MentionedAbbvieAmgenNovartisRocheAstraZenecaAscentage PharmaBeiGeneLigand PharmaTocris Bioscience Report Highlights:Global BCL-2 Inhibitors Market Opportunity: >US$ 4 Billion by 2025Insight on Market Indicators & Approved Drugs Sales DataGlobal BCL-2 Inhibitors Market Absolute Growth: >300% ( 97% CAGR, 2018 – 2020)Comprehensive Information On Ongoing Clinical TrialsGlobal BCL-2 inhibitors Clinical Trials By Company, Indication & PhaseVenetoclax Is The First Approved Drug Belonging To The Class Of BCL-2 Inhibitor The total volume of the agents available in the market has gradually increased by a certain amount of percentage and it is witnessed that the market has modestly moved faster in terms of size than any other cancer therapies, which altogether is driven by millions of factors around the world. There has been a substantial increase in the spending of the medicine, which is primarily driven by acceptance of the therapy by the developed markets and increased percentage of pharmerging markets. All the developed markets focused towards the inhibitor therapy have offset increased the production rate as well as commercialization strategies in order to end the struggle of the patients who have not been responding to any other cancer therapies available in the market. In the past few years, the number of BCL-2 inhibitor drugs that have reached the last stage of the development pipeline is witnessed to gradually impact the current growth rate of overall market. The arrival of novel drugs and expected arrival of novel active substances in the market are estimated to address significant unmet needs of the cancer patients across the globe. In addition to this, the global continued research with respect to the existing mechanism of action of drugs is estimated to cross the spectrum of a well-defined market towards a market that is huge and unavoidable. The global development of the market in different research centers and bio-pharmaceutical companies is estimated to challenge the current traditional cancer therapies. The market on a brighter side involves complete novel platform that is making the cancer patients observe high overall survival rate, five-year survival years, complete response and progression free survival. Also, association of the market with gene-editing technology such as CRISPR and technologically driven method artificial intelligence are estimated to transform the market by creating a plethora of medical applications. Healthcare advances delivered by the market are expected to treat a wide range of cancer types as well as provide the outcomes that were significantly required by the cancer patients for a long period of time. Compared to few decades ago with the start of the blooming market, the therapy has observed some real CAGR growth rate progression in different pharmaceutical markets of the world. At global level, the spending for conducting clinical research activities at different sites has increased to huge percentage over the past few years in some of the major pharmaceutical market and is estimated to grow more. Volume of the drugs available in the pharmaceutical markets has also grown to a certain amount over the past few years and is expected to grow more in the upcoming years. Overall growth of the volume of the drugs available in the market is estimated to be driven by the non-beneficial approval of drugs under other markets that account for majority of the cancer market, as well as the outlook of the healthcare benefits. Key Topics Covered: 1. Introduction to B Cell Lymphoma-2 (BCL-2) Inhibitors 2. BCL-2 Inhibitors – Mechanism of Action 3. Role of BCL-2 Inhibitors in Cancer Management 4. BCL-2 Inhibitors in Hematological Cancers 4.1 Overview 4.2 Impact of BCL-2 Inhibitors by Type of Hematological Cancer 4.3 Ongoing Research & Development 5. BCL-2 Inhibitors in Lung Cancers 5.1 Potential of BCL-2 Inhibitors as Lung Cancer Therapeutics 5.2 Current Research & Advancements 5.2.1 Venetoclax 5.2.2 Navitoclax 5.2.3 APG-1252 5.2.4 AT-101 6. BCL-2 Inhibitors in Other Cancers 6.1 Role of BCL-2 Inhibitors in Breast Cancer 6.2 BCL-2 Inhibitors for Ovarian Cancer 7. Global BCL-2 inhibitors Clinical Pipeline By Company, Indication & Phase 8. Marketed BCL-2 inhibitor Drug Clinical Insight: Venetoclax (VENCLYXTO) 9. Global BCL-2 Inhibitor Market Analysis 9.1 Market Overview 9.2 Current Market Scenrio 10. BCL-2 Inhibitors Market Regional Segmentation 10.1 US 10.2 Europe – Market Opportunity 10.3 Japan 10.4 China 10.5 Australia 11. Commercially Available BCL-2 Inhibitor Drug: Venclexta 12. BCL-2 Inhibitors Market Clinical Insight 13. Global BCL-2 Inhibitors Market Dynamics 14. Global BCL-2 Inhibitors Market Future Outlook 15. Competitive Landscape For more information about this report visit https://www.researchandmarkets.com/r/fdn3qh View source version on businesswire.com:https://www.businesswire.com/news/home/20210224005474/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: ONCOLOGY HEALTH PRACTICE MANAGEMENT GENETICS GENERAL HEALTH CLINICAL TRIALS PHARMACEUTICAL SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/24/2021 05:29 AM/DISC: 02/24/2021 05:29 AM http://www.businesswire.com/news/home/20210224005474/encenter_img Twitter By Digital AIM Web Support – February 24, 2021 TAGS  Facebook Twitter Previous articleEthisphere anuncia as Empresas mais éticas do mundo em 2021Next articleMoogsoft to Host ‘Coffee Break with Helen Beal’ Webinar Series Digital AIM Web Supportlast_img read more

The Donegal Road Safety Group honoured

first_img Twitter 70% of Cllrs nationwide threatened, harassed and intimidated over past 3 years – Report WhatsApp Google+ Facebook Minister McConalogue says he is working to improve fishing quota Facebook By News Highland – May 29, 2012 Man arrested in Derry on suspicion of drugs and criminal property offences released Twitter The Donegal Road Safety Group, responsible for the annual road safety events for students, has been honoured with a Civic Reception by Donegal County Council.Earlier this year the Council won the ‘Council of the Year’ award at the Local Authority Members Association Awards for its flagship Road Safety Road Show.The award  recognised the contribution the Road Safety Road Show has had in educating young drivers of the dangers on the roads.The council established the road safety group due in response to the upward surge in road deaths and to date over 12,000 young people have seen the hard hitting presentation.The initiative was introduced during Councillor John Boyle year as Mayor – he says it is having an impact and the road show should be compulsory for all young people seeking a licence:[podcast]http://www.highlandradio.com/wp-content/uploads/2012/05/johnrawaward.mp3[/podcast]One of those who contribute to the show is Dr Gerry Lane from Letterkenny General’s Emergency Department – he says the aim is to get the number of people dying on our roads down to zero:[podcast]http://www.highlandradio.com/wp-content/uploads/2012/05/drlane.mp3[/podcast] Pinterestcenter_img Pinterest Previous articleBoots Ireland cuts cost of prescription drugsNext articleHealth Minister: Cross border approach best option for Lifford Hospital News Highland Newsx Adverts The Donegal Road Safety Group honoured RELATED ARTICLESMORE FROM AUTHOR Google+ WhatsApp Dail hears questions over design, funding and operation of Mica redress scheme Need for issues with Mica redress scheme to be addressed raised in Seanad also Dail to vote later on extending emergency Covid powerslast_img read more

Federer says ‘epics’ keep him motivated after Australian Open thriller

first_img Promoted ContentCare To Try A Glow-In-The-Dark Doughnut?The Highest Paid Football Players In The World10 Risky Jobs Some Women Do10 Characters Who Would Make Astounding Disney PrincessesWho Earns More Than Ronaldo?20 Facts That’ll Change Your Perception Of “The Big Bang Theory”The Best Cars Of All TimeTop 7 Best Car Manufacturers Of All Time7 Universities In The World With The Highest Market Value6 Unforgettable Shows From The 90s That Need To Make A Comeback15 Action Heroes 25 Years Ago And Now13 kids at weddings who just don’t give a hoot Roger Federer lives to win titles, but five-set thrillers like his epic against John Millman at the Australian Open are also a key reason why he is still playing aged 38. The Swiss master looked out for the count at 4-8 down in a nailbiting fifth-set super tiebreaker against the gutsy Australian, but somehow found a way back to clinch the third-round clash 4-6, 7-6 (7⁄2), 6-4, 4-6, 7-6 (10⁄8). Roger Federer says his five-set epic against John Millman is why he continues to played aged 38 Federer admitted it was “extremely difficult” and he went through the full gamut of emotions. But that is how he likes it. He said the electric atmosphere on Rod Laver Arena and the thrill of a match that stretched for more than four hours was part of why he continues to play. “Yeah, no doubt,” said the 20-time Grand Slam winner. “I mean, in the moment itself, it’s very gruelling and, at times, very disappointing when you are in situations where you get broken in the fifth or you’re down in the super breaker and lose the first set. “That’s when you really start wondering, why couldn’t I close this match earlier and all these things? “Then all of a sudden you turn the whole thing around within, like, two minutes and it was so worthwhile, everything that I have gone through.” After 22 years of Grand Slam tennis, he said his motivation remained strong “because of winning titles, trying to win as many matches as possible, enjoy myself out on court”. “But also being in epic matches like this,” he added. “It doesn’t always have to be finals. As long as the crowds are into it, you have a great battle with an opponent who you really admire and respect, it’s a good feeling. “I’m happy I had that match. I hope I would feel the same way also if I would have lost, to be honest.” Federer had played 53 five-setters in his storied career before meeting Millman, winning 30 and losing 23, but few could match the intensity of the battle on Friday evening. Loading… Read Also: Aussie Open: Ruthless Nadal crushes Busta to reach last 16 Millman is one of the fittest players on tour and memorably beat Federer over four tight sets in the round of 16 at the US Open in 2018. “That’s why I mumbled something to him at the net just saying, ‘I have so much respect for you, and it’s such a pity, I’m so sorry, but well played’,” said the Swiss star. Federer next faces unseeded Hungarian Marton Fucsovics as he guns for a place in his 15th Australian Open quarter-final. FacebookTwitterWhatsAppEmail分享 last_img read more